Dorresteijn, Jannick A N

SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe

SCORE2 working group and ESC Cardiovascular risk collaboration, Hageman, S., Pennells, L., Ojeda, F., Kaptoge, S., Kuulasmaa, K., de Vries, T., Xu, Z., Kee, F., Chung, R., et al. (2021) · European Heart Journal

Health Promotion and Cardiovascular PreventionCardiovascular Health and Risk Factors

Cited by 1,810

SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe

SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, Pennells, L., Kaptoge, S., Østergaard, H. B., Read, S. H., Carinci, F., Franch-Nadal, J., Petitjean, C., Taylor, O., Hageman, S. H. J., et al. (2023) · European Heart Journal

Diabetes, Cardiovascular Risks, and LipoproteinsHealth Promotion and Cardiovascular Prevention

Cited by 329

Estimating treatment effects for individual patients based on the results of randomised clinical trials

Dorresteijn, J. A. N., Visseren, F. L. J., Ridker, P. M., Wassink, A. M. J., Paynter, N. P., Steyerberg, E. W., van der Graaf, Y., & Cook, N. R. (2011) · BMJ

Lipoproteins and Cardiovascular HealthStatistical Methods in Clinical Trials

Cited by 177

Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people

Jaspers, N. E. M., Blaha, M. J., Matsushita, K., van der Schouw, Y. T., Wareham, N. J., Khaw, K.-T., Geisel, M. H., Lehmann, N., Erbel, R., Jöckel, K.-H., et al. (2020) · European Heart Journal

Health Promotion and Cardiovascular PreventionLipoproteins and Cardiovascular Health

Cited by 120